There’s no doubt that the medical advances of the last hundred years have transformed the lives of most people on the planet. However, it can sometimes seem that for every step forward we take, there are two steps back, as new medical conditions appear. DBV-Technologies is dedicated to researching and finding solutions to the problem of food allergies. Allergies have been with us for years, but in recent times their prevalence has greatly increased. For instance, the prevalence of peanut allergy in children quadrupled between 1997 and 2008.
With increased numbers of people suffering from various allergies, so too the danger of anaphylactic shock becomes greater. It’s precisely to reduce this risk during the densensitization treatment of patients suffering from allergies that DBV-Technologies has produced its range of Viaskin® patches.
The Viaskin® patch (shown below) delivers antigens to the Langerhans cells, meaning that the allergens in question do not enter the bloodstream directly. This vastly cuts down on the likelihood of a severe allergic reaction being triggered during treatment or diagnosis of the allergy. The patch is being developed in peanut, house dust mite and cows’ milk protein form.